Delivery Order SPE2DB24D8002-SPE2DB24FJMNZ
Award Date
7/16/24
Potential Completion Date
7/17/24
Potential Value
$2.6K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award by the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense, to Dakota Drug, Inc., a self-certified small disadvantaged business. The $6,953.97 Firm Fixed Price delivery order contract is for the provision of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a pharmaceutical product. The contract has an ultimate completion date of October 25, 2023 and is not associated with a set-aside program. Dakota Drug, Inc. holds a significant single-award...
This federal contract award, identified as SPE2DX15D8001|SPE2DX24FBPWS, was issued by the Defense Logistics Agency (DLA) to the prime contractor Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a pharmaceutical product, with a ceiling value of $3,267.50. The contract has an ultimate completion date of October 16, 2023 and was awarded on October 13, 2023. This award is not associated with a set-aside program,...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML medical supplies. The contract has a ceiling value of $10,699.02 and a period of performance through April 28, 2023. This delivery order contract is part of Dakota Drug, Inc.'s larger indefinite delivery contract (IDC) with the DLA Troop Support Medical division, valued at...
This is a $2,732.81 firm fixed-price delivery order award to Dakota Drug, Inc., a self-certified small disadvantaged business, by the Defense Logistics Agency (DLA) Troop Support Medical division. The award is for the delivery of Actemra Actpen 162 mg/0.9 ml medication. Dakota Drug, Inc. holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, which enables the company to provide a wide range of pharmaceutical products,...
This federal contract award, identified as SPE2DX15D8001|SPE2DX24FBQCG, was made by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a pharmaceutical product, with a ceiling value of $7,645.48 and a completion date of December 1, 2023. Dakota Drug, Inc. is a critical supplier of pharmaceutical products, medical supplies, and healthcare...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML, a prescription medication. The contract, valued at $1,863.70, has an ultimate completion date of August 29, 2024. Dakota Drug, Inc. is an experienced prime contractor to the DLA Troop Support Medical, providing a wide range of pharmaceutical products, medical supplies, and healthcare...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML. The single-award Indefinite Delivery Contract (IDC) has a ceiling value of $1,571.74 and a performance period extending through March 4, 2025. This contract is part of the DLA Troop Support Medical's ECAT Generation V Program, which enables Dakota Drug, Inc. to efficiently deliver a comprehensive range of...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $1,571.74, is for the delivery of ACTEMRA ACTPEN 162 MG/0.9 ML 0.9ML pharmaceutical products. The contract has an ultimate completion date of January 14, 2025 and is part of the DLA Troop Support Medical's ECAT Generation V Program, a large indefinite delivery contract (IDC) that allows Dakota Drug, Inc. to...
This federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, was issued by the Defense Logistics Agency (DLA) and has a ceiling value of $1,571.74. The contract is a Delivery Order under the DLA Troop Support Medical's ECAT Generation V Program, an Indefinite Delivery Contract (IDC) with a performance period through December 31, 2025. This contract allows Dakota Drug, Inc. to provide a comprehensive range of pharmaceutical products, medical supplies, and...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $4,904.78, is for the delivery of Actemra Actpen 162 mg/0.9 ml, a pharmaceutical product, to support U.S. Armed Forces medical operations. The contract is a Firm Fixed Price Delivery Order with a performance period ending on May 22, 2024. Dakota Drug, Inc. has a significant single-award Indefinite Delivery Contract (IDC) with the...